No evidence seen for benefits of pancreatic cancer screening, according to study data.
A study conducted in a single institution sought to measure the impact including an oncology nurse navigator in the healthcare team has on patient treatment and outcomes.
A decision-analysis was used to determine which treatment of BR/LA PDAC was more efficacious and more cost-effective: neoadjuvant FOLFIRINOX vs surgery with GEM/CAPE vs surgery with gemcitabine.
In men, overweight and even higher normal weight is associated with an increased risk of future pancreatic cancer.
The goal of this study was to determine how molecular features change when PDAC progresses from a primary tumor to metastatic disease.